Literature DB >> 33723406

The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs.

Eman Sami1, Danielle Bogan2, Alfredo Molinolo3, Jim Koziol4, Wael M ElShamy5.   

Abstract

Triple-negative breast cancer (TNBCs) display lung metastasis tropism. However, the mechanisms underlying this organ-specific pattern remains to be elucidated. We sought to evaluate the utility of blocking extravasation to prevent lung metastasis. To identify potential geminin overexpression-controlled genetic drivers that promote TNBC tumor homing to lungs, we used the differential/suppression subtractive chain (D/SSC) technique. A geminin overexpression-induced lung metastasis gene signature consists of 24 genes was discovered. We validated overexpression of five of these genes (LGR5, HAS2, CDH11, NCAM2, and DSC2) in worsening lung metastasis-free survival in TNBC patients. Our data demonstrate that LGR5-induced β-catenin signaling and stemness in TNBC cells are geminin-overexpression dependent. They also demonstrate for the first-time expression of RSPO2 in mouse lung tissue only and exacerbation of its secretion in the circulation of mice that develop geminin overexpressing/LGR5+-TNBC lung metastasis. We identified a novel extravasation receptor complex, consists of CDH11, CD44v6, c-Met, and AXL on geminin overexpressing/LGR5+-TNBC lung metastatic precursors, inhibition of any of its receptors prevented geminin overexpressing/LGR5+-TNBC lung metastasis. Overall, we propose that geminin overexpression in normal mammary epithelial (HME) cells promotes the generation of TNBC metastatic precursors that home specifically to lungs by upregulating LGR5 expression and promoting stemness, intravasation, and extravasation in these precursors. Circulating levels of RSPO2 and OPN can be diagnostic biomarkers to improve risk stratification of metastatic TNBC to lungs, as well as identifying patients who may benefit from therapy targeting geminin alone or in combination with any member of the newly discovered extravasation receptor complex to minimize TNBC lung metastasis.
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc. part of Springer Nature.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33723406     DOI: 10.1038/s41417-021-00311-x

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  71 in total

Review 1.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

2.  β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.

Authors:  Jinhua Xu; Yinghua Chen; Dezheng Huo; Andrey Khramtsov; Galina Khramtsova; Chunling Zhang; Kathleen H Goss; Olufunmilayo I Olopade
Journal:  Mol Carcinog       Date:  2015-02-08       Impact factor: 4.784

3.  R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling.

Authors:  Kendra S Carmon; Xing Gong; Qiushi Lin; Anthony Thomas; Qingyun Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-21       Impact factor: 11.205

4.  LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells.

Authors:  Susumu Nakata; Benito Campos; Josephine Bageritz; Justo Lorenzo Bermejo; Natalia Becker; Felix Engel; Till Acker; Stefan Momma; Christel Herold-Mende; Peter Lichter; Bernhard Radlwimmer; Violaine Goidts
Journal:  Brain Pathol       Date:  2012-08-30       Impact factor: 6.508

5.  Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.

Authors:  Alessandra Gennari; PierFranco Conte; Riccardo Rosso; Cinzia Orlandini; Paolo Bruzzi
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

6.  Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

Authors:  Cecile Chartier; Janak Raval; Fumiko Axelrod; Chris Bond; Jennifer Cain; Cristina Dee-Hoskins; Shirley Ma; Marcus M Fischer; Jalpa Shah; Jie Wei; May Ji; Andrew Lam; Michelle Stroud; Wan-Ching Yen; Pete Yeung; Belinda Cancilla; Gilbert O'Young; Min Wang; Ann M Kapoun; John Lewicki; Timothy Hoey; Austin Gurney
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 12.701

7.  Identification of stem cells in small intestine and colon by marker gene Lgr5.

Authors:  Nick Barker; Johan H van Es; Jeroen Kuipers; Pekka Kujala; Maaike van den Born; Miranda Cozijnsen; Andrea Haegebarth; Jeroen Korving; Harry Begthel; Peter J Peters; Hans Clevers
Journal:  Nature       Date:  2007-10-14       Impact factor: 49.962

Review 8.  The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength.

Authors:  Wim de Lau; Weng Chuan Peng; Piet Gros; Hans Clevers
Journal:  Genes Dev       Date:  2014-02-15       Impact factor: 11.361

Review 9.  Breast cancer lung metastasis: Molecular biology and therapeutic implications.

Authors:  Liting Jin; Bingchen Han; Emily Siegel; Yukun Cui; Armando Giuliano; Xiaojiang Cui
Journal:  Cancer Biol Ther       Date:  2018-04-30       Impact factor: 4.742

10.  WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.

Authors:  Lorenzo Castagnoli; Valeria Cancila; Sandra L Cordoba-Romero; Simona Faraci; Giovanna Talarico; Beatrice Belmonte; Marilena V Iorio; Matteo Milani; Tatiana Volpari; Claudia Chiodoni; Alfredo Hidalgo-Miranda; Elda Tagliabue; Claudio Tripodo; Sabina Sangaletti; Massimo Di Nicola; Serenella M Pupa
Journal:  Oncogene       Date:  2019-01-31       Impact factor: 9.867

View more
  5 in total

1.  Gene expression profiling and protein-protein interaction analysis reveals the dynamic role of MCM7 in Alzheimer's disorder and breast cancer.

Authors:  Navneeth Sriram; Sunny Mukherjee; Mahesh Kumar Sah
Journal:  3 Biotech       Date:  2022-06-10       Impact factor: 2.893

2.  Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation.

Authors:  H Vihervuori; K Korpinen; T A Autere; H Repo; K Talvinen; P Kronqvist
Journal:  Breast Cancer Res Treat       Date:  2022-10-19       Impact factor: 4.624

Review 3.  Targeting HMGB1: An available Therapeutic Strategy for Breast Cancer Therapy.

Authors:  Haonan Dong; Lu Zhang; Suling Liu
Journal:  Int J Biol Sci       Date:  2022-05-09       Impact factor: 10.750

4.  Pan-cancer assessment of mutational landscape in intrinsically disordered hotspots reveals potential driver genes.

Authors:  Haozhe Zou; Tao Pan; Yueying Gao; Renwei Chen; Si Li; Jing Guo; Zhanyu Tian; Gang Xu; Juan Xu; Yanlin Ma; Yongsheng Li
Journal:  Nucleic Acids Res       Date:  2022-05-20       Impact factor: 19.160

5.  Verification and Validation of a Four-Gene Panel as a Prognostic Indicator in Triple Negative Breast Cancer.

Authors:  Mamta Pariyar; Rick F Thorne; Rodney J Scott; Kelly A Avery-Kiejda
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.